← Back to Patent Explorer
US4125614A Expired / Lapsed US ⏱️ 0.0 years remaining

Thiazolidine derivatives

Assignee: Hoechst AG
•
Filing: 1977-04-19
•
Granted: 1978-11-14
•
Expires: 1997-04-19
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention relates to thiazolidine derivatives having in 4-position a hydroxy group and a 3'-sulphamyl-phenyl substituent, in 2-position an imino group and in 1-position an aliphatic or cycloaliphatic substituent. Said thiazolidines have diuretic activity. The invention also relates to a process for the manufacture of said compounds.

Inventors

  • 👤 Hans-Jochen Lang
  • 👤 Roman Muschaweck

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-08 11:22
CPC Classifications
C; C07; C07D; C07D417/00; C07D417/02; C07D417/12; C07D277/00; C07D277/02; C07D277/08; C07D277/12; C07D277/18

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 159 words
A thiazolidine compound of the formula ##STR511## or an acid addition salt thereof with a pharmaceutically acceptable acid, wherein R 1 and R 2 , taken together, are alkylene having 2 to 4 carbon atoms; R 3 is hydrogen or alkyl having 1 to 2 carbon atoms; R 5 is hydrogen and R 4 is hydrogen, alkyl, or alkenyl having up to 6 carbon atoms, or such alkyl or alkenyl which is substituted by alkoxy having 1 to 4 carbon atoms, or R 5 is hydrogen and R 4 is cycloalkyl having 3, 5, or 6 carbon atoms, cyclohexylmethyl, phenyl, phenylalkyl having 1 to 3 carbon atoms in the alkyl moiety, or such phenylalkyl the phenyl ring of which is substituted by one or two halogen atoms, by one to three methoxy groups, by one alkyl group, or by one methylenedioxy group, or R 4 and R 5 are each methyl; and Y is hydrogen, halogen, methyl or trifluoromethyl.
Claim 2
Dependent Claim 159 words
A thiazolidine compound of the formula ##STR511## or an acid addition salt thereof with a pharmaceutically acceptable acid, wherein R 1 and R 2 , taken together, are alkylene having 2 to 4 carbon atoms; R 3 is hydrogen or alkyl having 1 to 2 carbon atoms; R 5 is hydrogen and R 4 is hydrogen, alkyl, or alkenyl having up to 6 carbon atoms, or such alkyl or alkenyl which is substituted by alkoxy having 1 to 4 carbon atoms, or R 5 is hydrogen and R 4 is cycloalkyl having 3, 5, or 6 carbon atoms, cyclohexylmethyl, phenyl, phenylalkyl having 1 to 3 carbon atoms in the alkyl moiety, or such phenylalkyl the phenyl ring of which is substituted by one or two halogen atoms, by one to three methoxy groups, by one alkyl group, or by one methylenedioxy group, or R 4 and R 5 are each methyl; and Y is hydrogen, halogen, methyl or trifluoromethyl.
Claim 3
Dependent Claim 21 words
A compound as claimed in claim 1 wherein R 1 and R 2 taken together are alkylene having 2 carbon atoms.
Claim 4
Dependent Claim 21 words
A compound as claimed in claim 1 wherein R 1 and R 2 taken together are alkylene having 3 carbon atoms.
Claim 5
Dependent Claim 20 words
A compound as in claim 1 wherein R 1 and R 2 taken together are alkylene having 4 carbon atoms.
Claim 6
Dependent Claim 27 words
A pharmaceutical composition for inducing salidiuresis, said composition comprising a salidiuretically effective amount of a compound as in claim 1 in combination with a pharmaceutically acceptable carrier.
Claim 7
Dependent Claim 17 words
A pharmaceutical composition as in claim 5 containing from 10 mg to 100 mg of said compound.
Claim 8
Dependent Claim 25 words
The method of inducing salidiuresis in a patient which comprises administering to said patient a salidiuretically effective amount of a compound as in claim 1.
Claim 9
Dependent Claim 10 words
A compound as claimed in claim 1, which is 3-(4-chloro-3-sulfamoylphenyl)-3-hydroxy-2,3,5,6-tetrahydroimidazo[2,1-b]-thiazole-hydrobromide.
Claim 10
Dependent Claim 10 words
A compound as claimed in claim 1, which is 3-(4-chloro-3-sulfamoylphenyl)-3-hydroxy-2,3,6,7-tetrahydro-5H-thiazolo-[3,2-a]-pyrimidine-hydrochloride.
Claim 11
Dependent Claim 10 words
A compound as claimed in claim 1, which is 3-(4-chloro-3-sulfamoylphenyl)-6,6-dimethyl-3-hydroxy-2,3,5,6-tetrahydro-imidazo[2,1-b]-thiazole-hydrobromide.

References Cited (Backward Citations)

US3853872A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1981-11-13 1982-05-15 1982-11-14 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1985-11-13 1986-05-15 1986-11-14 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1989-11-13 1990-05-15 1990-11-14 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag